Summary
NHS England Evidence Review
Rituximab for acute immune thrombotic thrombocytopaenic purpura
Drafted: July 2021
Prepared by Solutions for Public Health (SPH) on behalf of NHS England Specialised Commissioning
NHS England Evidence Review
Rituximab for acute immune thrombotic thrombocytopaenic purpura
Drafted: July 2021
Prepared by Solutions for Public Health (SPH) on behalf of NHS England Specialised Commissioning